Evaluating VRT106 with chemotherapy for pancreatic cancer
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
This study is testing if a new virus treatment combined with chemotherapy can help people with operable pancreatic cancer feel better and live longer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06758544 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to assess the efficacy and safety of VRT106, an oncolytic virus, in combination with chemotherapy for patients with resectable pancreatic cancer. It is a single-center, open-label study that will enroll 18 participants, who will undergo a screening period followed by treatment and safety follow-up. The study will monitor patient responses and safety outcomes over a defined period, including survival follow-ups every three months.
Who should consider this trial
Good fit: Ideal candidates are males and females aged 18-75 with a clinical diagnosis of pancreatic cancer and an ECOG score of 0 or 1.
Not a fit: Patients who have previously received oncolytic virus treatment or systemic therapy for pancreatic cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with resectable pancreatic cancer.
How similar studies have performed: While this approach is innovative, similar studies using oncolytic viruses in cancer treatment have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures. 2. Males and females at 18-75 years of age, inclusive, at the Screening Visit. 3. Have a clinical diagnosis of pancreatic cancer. 4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. 5. Expected survival time of≥6 months. 6. No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions. Exclusion Criteria: 1. Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer. 2. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation. 3. Immunocompromised patients. 4. Known alcohol or drug dependency. 5. Women who are pregnant or breastfeeding.
Where this trial is running
Guangzhou, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Chen RF Prof.
- Email: chenrf63@163.com
- Phone: 020-83525210
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.